Join
Live feed
·
PRReleasevia Quantisnow
BeyondSpring Inc. logo

BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors

ByQuantisnow·Wall Street's wire, on your screen.
BYSI· BeyondSpring Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BYSI (BeyondSpring Inc.) and more on Quantisnow.